Navigation Links
New hormone therapy shows promise for menopausal symptoms in animal model
Date:12/12/2012

WINSTON-SALEM, N.C., Dec. 13, 2012 Investigators at Wake Forest Baptist Medical Center have concluded research on a new postmenopausal hormone therapy that shows promise as an effective treatment for menopausal symptoms and the prevention of osteoporosis without increasing the risk for heart disease or breast cancer.

Traditional forms of hormone therapy (HT) provide the benefits of symptom relief, prevention of osteoporosis and prevention of atherosclerosis, but increase the risk of uterine cancer (with estrogens alone) or breast cancer (with combined estrogens and progestins). Thus, the risk-benefit ratio of traditional HT is not ideal. Less potent plant-derived estrogens are relatively safe, but less effective. Selective estrogen receptor modulators (SERMs) provide both beneficial effects and adverse effects, but the ideal treatment has proven elusive, said J. Mark Cline, D.V.M., Ph.D., one of the co-authors.

The Wake Forest Baptist team worked in partnership with the pharmaceutical company Pfizer to explore a new strategy, termed a Tissue Selective Estrogen Combination (TSEC). Using this strategy, a conventional estrogen (CEE) was combined with a bone-protective SERM-like drug, bazedoxifene acetate (BZA), to produce a complementary pattern of tissue effects that maximize the benefits of HT while avoiding the risk. The study involved a 20-month randomized, parallel-arm trial which has a comparison group and at least one new or active therapy group in postmenopausal nonhuman primates, designed to determine the effect of TSEC treatment on the breast, uterus and cardiovascular system.

The TSEC strategy has been evaluated in the Selective estrogens, Menopause, And Response to Therapy (SMART) phase 3 trials involving more than 6,000 women. Cline said the Wake Forest Baptist nonhuman primate trials are important because they can address tissue responses directly, whereas studies in women use clinical outcomes that may require many years to provide conclusive results.

The Wake Forest Baptist findings are discussed in separate papers, both published recently in Menopause: The Journal of The North American Menopause Society.

Prior work by Cline in the 1990s demonstrated the adverse effect of a widely used estrogens and estrogen-progestin combination on the breast, a finding that was predictive of the breast cancer patterns later found in the Women's Health Initiative. In contrast to that finding, the TSEC strategy is anticipated to reduce breast cancer risk. "Remarkably, BZA overrides the adverse effects of CEE at the level of gene expression in the breast, suppressing abnormal tissue growth," Cline said.

Lead investigator Thomas B. Clarkson, D.V.M., is hopeful about the promise of this new approach. "The findings are encouraging for postmenopausal women," he said. "We believe that women can be given CEE along with BZA to protect against breast cancer and uterine cancer, without adversely affecting the cardiovascular system, but more research is necessary."


'/>"/>

Contact: Bonnie Davis
bdavis@wakehealth.edu
336-716-4977
Wake Forest Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Hormone Replacement Clinic, Renew Health and Wellness Opens in Richmond, Virginia. New Center Specializes in Anti-Aging Therapies for both Women and Men.
2. Hormone Replacement Clinic, Renew Health and Wellness Opens in St. Louis, Missouri Area. New Center Specializes in Anti-Aging Therapies for both Women and Men.
3. Too Little Sleep Spurs Appetite-Boosting Hormones: Study
4. High hormone levels put young black males at risk for cardiovascular disease
5. Could Hormone Spray Help Men Stay, Not Stray?
6. Feel-good hormone helps to jog the memory
7. Pregnancy Hormone Shows Promise as Heart Failure Drug
8. Metabolic syndrome makes a difference in hormone therapy risk
9. Hormone Replacement Therapy: Safe or Not?
10. Mild increases in thyroid-stimulating hormone not harmful in the elderly
11. Role of hormones, potential new treatments topic of UH lecture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... Sterling Global Products is launching a Kickstarter campaign focused on “PAW Patrol ... campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco . The campaign will ... raise $1,000 per day for a total of $25,000. The funds will be used ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... of its services to provide one resource, from start to finish, for Life ... Life Safety Statement of Condition surveys requested by the Joint Commission, and fire ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... organization, is pleased to welcome new Partner Firm Austin & Co., Inc. ... approach to insurance, employee benefits, HR consulting, benefits technology, and beyond. As ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free Procedures, ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of quality ... ever be totally eliminated, many human performance problems can be prevented. , How to ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Global Paclitaxel Market ... profiles 12 companies and the Paclitaxel analysis in this ... the industry and its players. This is ... nature, details the current state of the industry while ... classifications, applications and industry chain structure. The Paclitaxel market ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
(Date:5/23/2016)... Clarifying Vision - Prospects and Developments in ... What can be expected from the Ophthalmic ... the fastest rates? This visiongain report shows ... and prospects. ,Our 190-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology: